CPKC sees strong start to grain movement in October

Oct 18, 2023

With the harvest wrapped up in many areas, the country elevator system is seeing more deliveries headed to Port.

Elizabeth Hucker, CPKC's assistant vice-president of sales and marketing for bulk says they started the month of October out strong.

"So in week 10, CPKC moved approximately 569,000 metric tons of grain and grain products to destinations in Thunder Bay, Vancouver, and throughout North America. This was our second largest screen shipping week of the 2023 - 2024 grain crop year."

She adds that grain movement at the ports has been going relatively smoothly.

"No impacts just yet have been seen in Vancouver, although we are about to get into the rainy season. So we're closely monitoring any impacts to the loading of grain to vessels during the rain. Thunder Bay is moving tremendously well. We're seeing high volumes to Thunder Bay to satisfy some of that European demand before the normal shutdown that comes as winter approaches us in December."She adds that overall efficiency from all players in the supply chain is key.

Source : Pembinavalley online

Video: Finding a Balance of Innovation and Regulation - Dr. Peter Facchini

Regulations help markets and industry exist on level playing fields, keeping consumers safe and innovation from going too far. However, incredibly strict regulations can stunt innovation and cause entire industries to wither away. Dr. Peter James Facchini brings his perspective on how existing regulations have slowed the advancement of medical developments within Canada. Given the international concern of opium poppy’s illicit potential, Health Canada must abide by this global policy. But with modern technology pushing the development of many pharmaceuticals to being grown via fermentation, is it time to reconsider the rules?

Dr. Peter James Facchini leads research into the metabolic biochemistry in opium poppy at the University of Calgary. For more than 30 years, his work has contributed to the increased availability of benzylisoquinoline alkaloid biosynthetic genes to assist in the creation of morphine for pharmaceutical use. Dr. Facchini completed his B.Sc. and Ph.D. in Biological Sciences at the University of Toronto before completing Postdoctoral Fellowships in Biochemistry at the University of Kentucky in 1992 & Université de Montréal in 1995.